1097-0142/asset/cover.gif?v=1&s=a7299bc18f075294c232ade468773cd0672bd470 "Cancer")
Fax: (713) 792-7586
1097-0142/asset/olbannerleft.gif?v=1&s=ca681f5719430b26e1bc15e9ea4c9fc0a7110104)
1097-0142/asset/olbannerright.gif?v=1&s=8142566facf7e76aef9be6c51162a2e920b3b9f9)
Original Article
You have full text access to this OnlineOpen article
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium
Article first published online: 25 JUN 2003
DOI: 10.1002/cncr.11561
Copyright © 2003 American Cancer Society
Additional Information
How to Cite
Schmandt, R. E., Broaddus, R., Lu, K. H., Shvartsman, H., Thornton, A., Malpica, A., Sun, C., Bodurka, D. C. and Gershenson, D. M. (2003), Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-β in ovarian serous carcinoma and normal ovarian surface epithelium. Cancer, 98: 758–764. doi: 10.1002/cncr.11561
Publication History
- Issue published online: 1 AUG 2003
- Article first published online: 25 JUN 2003
- Manuscript Accepted: 7 MAY 2003
- Manuscript Revised: 2 MAY 2003
- Manuscript Received: 24 JAN 2003
Funded by
- M. D. Anderson Blanton-David Ovarian Cancer Research Program
- Beth Liebman and the Elizabeth Fund
- Ovarian Cancer Research Fund
- Abstract
- Article
- References
- Cited By
Cited in:
- CrossRef
This article has been cited by:
- 1, , , , , , , , , Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube, Gynecologic Oncology, 2012,
- 2, , , , , , , Platelet-Derived Growth Factor Gene Polymorphisms in Patients with Ovarian Cancer, Clinical Ovarian Cancer, 2012,
- 3
- 4, , , , , , , Recurrence patterns and prognosis of endometrial stromal sarcoma and the potential of tyrosine kinase-inhibiting therapy, Gynecologic Oncology, 2011, 121, 2, 323
- 5, , , , , , , , c-kit (CD117) Expression in Human Tumors and its Prognostic Value: An Immunohistochemical Analysis, Pathology & Oncology Research, 2010, 16, 3, 295
- 6, , , , , Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3, Acta Biochimica et Biophysica Sinica, 2010, 42, 9, 593
- 7, c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications, Leukemia Research, 2009, 33, 1, 5
- 8, , , , Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of α6β1 integrin, The International Journal of Biochemistry & Cell Biology, 2009, 41, 5, 1034
- 9, , , , , , , KIT is an Independent Prognostic Marker for Pancreatic Endocrine Tumors, The American Journal of Surgical Pathology, 2009, 33, 10, 1562
- 10, , , , , , KIT/PDGFRA Expression and Mutation in Testicular Seminoma and Ovarian Dysgerminoma, The Korean Journal of Pathology, 2009, 43, 6, 528
- 11, , , , , The antitumor effect of bromophenol derivatives in vitro and Leathesia nana extract in vivo, Chinese Journal of Oceanology and Limnology, 2009, 27, 2, 277
- 12, , , , Advanced small cell carcinoma of the ovary in a seventeen-year-old female, successfully treated with surgery and multi-agent chemotherapy, Pediatric Blood & Cancer, 2008, 50, 5Direct Link:
- 13, , , , , , , , , , , Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis, Cancer, 2008, 113, 4Direct Link:
- 14, , , Primary Ovarian Insufficiency Associated with Imatinib Therapy, New England Journal of Medicine, 2008, 358, 10, 1079
- 15, , Targeting signaling pathways in ovarian cancer, Expert Opinion on Therapeutic Targets, 2008, 12, 3, 353
- 16, The Promise and Perils of ‘Targeted Therapy’ of Advanced Ovarian Cancer, Oncology, 2008, 74, 1-2, 1
- 17, , , , , , , , , , , A prospective analysis of imatinib-induced c-kit modulation in ovarian cancer, Cancer, 2007, 110, 2Direct Link:
- 18, , , , , , , , Expression of platelet-derived growth factors and their receptors in ovarian clear-cell carcinoma and its putative precursors, Modern Pathology, 2007,
- 19, , , , , , , Germline stem cells and neo-oogenesis in the adult human ovary, Developmental Biology, 2007, 306, 1, 112
- 20, , , , , , , , , , , , , , , Ido serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells, International Congress Series, 2007, 1304, 262
- 21, , , Novel targeted therapies in epithelial ovarian cancer: from basic research to the clinic, Expert Review of Endocrinology & Metabolism, 2007, 2, 2, 225
- 22, , , , , , , Detection of C-KIT (CD117) molecule in benign and malignant salivary gland tumours, Oral Oncology, 2006, 42, 1, 56
- 23, , , , Expression and Mutational Analysis of c-kit in Ovarian Surface Epithelial Tumors, Journal of Korean Medical Science, 2006, 21, 1, 81
- 24, , , , , , , , Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers, Gynecologic Oncology, 2006, 101, 1, 126
- 25, , , , , , , , , The AP-2γ transcription factor is upregulated in advanced-stage ovarian carcinoma, Gynecologic Oncology, 2006, 100, 3, 462
- 26, , , , , , , Autocrine activation of PDGFRα promotes the progression of ovarian cancer, Oncogene, 2005, 25, 14, 2060
- 27, , , , , , , , Bovine papillomavirus E5 oncoprotein binds to the activated form of the platelet-derived growth factor β receptor in naturally occurring bovine urinary bladder tumours, Oncogene, 2005, 25, 8, 1251
- 28, , , , , , Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRα, and PDGFRβ in ovarian cancers, Human Pathology, 2005, 36, 3, 242
- 29, , , , , , Expression of c-kit in uterine carcinosarcoma, Gynecologic Oncology, 2005, 96, 1, 210
- 30, , , , , , , , , , Expression of CD117 (c-kit) receptor in dysgerminoma of the ovary: diagnostic and therapeutic implications, Modern Pathology, 2005, 18, 11, 1411
- 31, , , , Expression of KIT (CD117) in Renal Cell Carcinoma and Renal Oncocytoma, Oncology, 2005, 68, 2-3, 269
- 32, , Imatinib mesylate and its potential implications for gynecologic cancers, Current Treatment Options in Oncology, 2005, 6, 2, 115
- 33, Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: A clinicopathologic study, Gynecologic Oncology, 2005, 98, 3, 396
- 34, , Investigational agents for epithelial ovarian cancer, Expert Review of Anticancer Therapy, 2005, 5, 5, 855
- 35, , , Kit (CD117) immunoreactivity is rare in renal cell and upper urinary tract transitional cell carcinomas, BJU International, 2005, 95, 3Direct Link:
- 36, , KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation, Applied Immunohistochemistry & Molecular Morphology, 2005, 13, 3, 205
- 37, , , , , , , , , , , Synthesis and in vitro examination of [124I]-, [125I]- and [131I]-2-(4-iodophenylamino) pyrido[2,3-d]pyrimidin-7-one radiolabeled Abl kinase inhibitors, Nuclear Medicine and Biology, 2005, 32, 4, 313
- 38, , , , , , The Impact of C-kit and Ki-67 Expression on Patients Prognosis in Advanced Ovarian Serous Carcinoma, International Journal of Gynecological Pathology, 2005, 24, 3, 228
- 39, , , Analysis of KIT (CD117) expression in gallbladder carcinomas by tissue microarray, European Journal of Surgical Oncology (EJSO), 2004, 30, 8, 847
- 40, , , , , , , , , Expression of imatinib mesylate-targeted kinases in endometrial carcinoma, Gynecologic Oncology, 2004, 95, 1, 32
- 41, , , , , , , Genetic alterations and protein expression of KIT and PDGFRA in serous ovarian carcinoma, British Journal of Cancer, 2004, 91, 12, 2048
- 42, , , , Targeted therapy for epithelial ovarian cancer: Current status and future prospects, International Journal of Gynecological Cancer, 2003, 13, 6Direct Link: